Goodrx, Novo Nordisk Partner to Offer Ozempic, Wegovy

Prescription savings platform GoodRx is partnering with pharmaceutical giant Novo Nordisk to make Ozempic and Wegovy pens available to eligible self-paying patients for $499 per month at retail pharmacies nationwide. The company said this collaboration lowers the cost of two of the most sought-after GLP-1 medications, making them more accessible to people with inadequate insurance coverage.

“Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,” Wendy Barnes, president and CEO of GoodRx, said in a statement. “By partnering with Novo Nordisk, we’re taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them. It’s a powerful example of how the GoodRx platform can deliver savings at scale, bridging gaps in coverage and ensuring more people can get the care they deserve.”

The collaboration comes as GLP-1 usage continues to rise. According to the CDC, 26.5% of adults with diabetes in 2024 reported using GLP-1 injectables. Use increased with age among adults 18 to 34 (25.3%) and 50 to 64 (33.3%) but declined among those 65 and older (20.8%). Among adults with diabetes, patients who took insulin (31.3%) or oral glucose-lowering medications (28.1%) were more likely to use GLP-1 injectables than those not taking those medications (24.5% and 22.2%, respectively).

Both companies have recently pursued new initiatives in healthcare access. In June, GoodRx launched a subscription service for erectile dysfunction and introduced GoodRx Community Link, a program designed to help independent community pharmacies navigate reimbursement challenges. Community Link uses a cost-plus pricing model based on the National Average Drug Acquisition Cost to provide predictable pricing and favorable economics. Earlier in January, the company launched GoodRx for Pets, aimed at making pet medications more affordable and convenient, with home delivery options for owners.

Novo Nordisk, meanwhile, collaborated with WeightWatchers in June to make Wegovy available through NovoCare Pharmacy. That partnership integrates WeightWatchers’ telehealth program, enabling new uninsured or self-paying patients to access Wegovy for a monthly fee. According to Novo Nordisk, this offering helps patients who had been prescribed unapproved “semaglutide” transition to FDA-approved Wegovy. The drug is dispensed via CenterWell Pharmacy, which manages prescription fulfillment and delivery for NovoCare Pharmacy.